Articles from MediBeacon Inc.

ST. LOUIS, Feb. 10, 2026 (GLOBE NEWSWIRE) -- MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today announced that the peer-reviewed transdermal GFR measurement article published in the Journal of the American Society of Nephrology (JASN) has been recognized as one of five 2025 Editor’s Choice articles.1

ST. LOUIS, Dec. 16, 2025 (GLOBE NEWSWIRE) -- MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today announced the U.S. Food and Drug Administration (FDA) has approved the next generation MediBeacon® TGFR™ System including the latest TGFR™ Reusable Sensor.

ST. LOUIS, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today announced that data from the Company’s transdermal GFR technology has been accepted for an oral presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, November 5-9, 2025.

ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, announced that MediBeacon’s Lumitrace® (relmapirazin) injection, a non-radioactive, non-iodinated fluorescent GFR agent, has been approved by the National Medical Products Administration (NMPA). Lumitrace will be sold as an integral component of the Transdermal GFR System in China.